• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

ACS Nano . Early Detection of SARS-CoV-2 Seroconversion in Humans with Aggregation-Induced Near-Infrared Emission Nanoparticle-Labeled Lateral Flow

tetano

Editor, Senior Moderator
ACS Nano


. 2021 Apr 30.
doi: 10.1021/acsnano.1c01932. Online ahead of print.
Early Detection of SARS-CoV-2 Seroconversion in Humans with Aggregation-Induced Near-Infrared Emission Nanoparticle-Labeled Lateral Flow Immunoassay


Rui Chen[SUP] 1 [/SUP], Cuiping Ren[SUP] 2 [/SUP], Miao Liu[SUP] 1 [/SUP], Xiaopeng Ge[SUP] 3 [/SUP], Mingsheng Qu[SUP] 2 [/SUP], Xiaobo Zhou[SUP] 1 [/SUP], Mifang Liang[SUP] 4 [/SUP], Yan Liu[SUP] 2 [/SUP], Fuyou Li[SUP] 1 [/SUP]



Affiliations

Abstract

An outbreak of coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses great threats to human health and the international economy. To reduce large-scale infection and transmission risk of SARS-CoV-2, a simple, rapid, and sensitive serological diagnostic method is urgently needed. Herein, an aggregation-induced emission (AIE) nanoparticle (AIE[SUB]810[/SUB]NP, ?[SUB]em[/SUB] = 810 nm)-labeled lateral flow immunoassay was designed for early detection of immunoglobulin M (IgM) and immunoglobulin G (IgG) against SARS-CoV-2 in clinical serum samples. Using a near-infrared (NIR) AIE nanoparticle as the fluorescent reporter (?? = 145 nm), the autofluorescence from the nitrocellulose membrane and biosample and the excitation background noise were effectively eliminated. After optimization, the limit of detection of IgM and IgG is 0.236 and 0.125 ?g mL[SUP]-1[/SUP], respectively, commensurate with that of the enzyme-linked immunosorbent assay (ELISA) (0.040 and 0.039 ?g mL[SUP]-1[/SUP]). The sensitivity of the proposed AIE[SUB]810[/SUB]NP-based test strip for detecting IgM and IgG is 78 and 95% (172 serum samples), commensurate with that of ELISA (85 and 95%) and better than that of a commercial colloidal gold nanoparticle (AuNP)-based test strip (41 and 85%). Importantly, the time of detecting IgM or IgG with an AIE[SUB]810[/SUB]NP-based test strip in sequential clinical samples is 1-7 days after symptom onset, which is significantly earlier than that with a AuNP-based test strip (8-15 days). Therefore, the NIR-emissive AIE nanoparticle-labeled lateral flow immunoassay holds great potential for early detection of IgM and IgG in a seroconversion window period.

Keywords: COVID-19; NIR-emissive AIE nanoparticle; SARS-CoV-2; early detection; lateral flow immunoassay.
 
Back
Top Bottom